Introduction In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events (AEs) and the incidence of AEs. Data were compared for patients treated with add-on BRV after 1-2 (early add-on) and >= 3 (late add-on) prior antiseizure medications. Results A total of 1029 patients with focal epilepsy were included in the study, of whom 176 (17.1%) received BRV as early add-on treatment. The median daily dose of BRV at 12 months was 125 (100-200) mg in the early add-on group and 200 (100-200) in the late add-on group (p < 0.001). Sustained seizure response was reached by 97/161 (60.3%) of patients in the early add-on group and 286/833 (34.3%) of patients in the late add-on group (p < 0.001). Sustained seizure freedom was achieved by 51/161 (31.7%) of patients in the early add-on group and 91/833 (10.9%) of patients in the late add-on group (p < 0.001). During the 1-year study period, 29 (16.5%) patients in the early add-on group and 241 (28.3%) in the late add-on group discontinued BRV (p = 0.001). Adverse events were reported by 38.7% and 28.5% (p = 0.017) of patients who received BRV as early and late add-on treatment, respectively. Conclusion Brivaracetam was effective and well tolerated both as first add-on and late adjunctive treatment in patients with focal epilepsy.

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study / S. Lattanzi, L. Canafoglia, M.P. Canevini, S. Casciato, E. Cerulli Irelli, V. Chiesa, F. Dainese, G. De Maria, G. Didato, G. Di Gennaro, G. Falcicchio, M. Fanella, E. Ferlazzo, M. Gangitano, A. La Neve, O. Mecarelli, E. Montalenti, A. Morano, F. Piazza, C. Pizzanelli, P. Pulitano, F. Ranzato, E. Rosati, L. Tassi, C. Di Bonaventura, A. Alicino, M. Ascoli, G. Assenza, F. Avorio, V. Badioni, P. Banfi, E. Bartolini, L.M. Basili, V. Belcastro, S. Beretta, I. Berto, M. Biggi, G. Billo, G. Boero, P. Bonanni, J. Bongorno, F. Brigo, E. Caggia, C. Cagnetti, C. Calvello, E. Cesnik, G. Chianale, D. Ciampanelli, R. Ciuffini, D. Cocito, D. Colella, M. Contento, C. Costa, E. Cumbo, A. D’Aniello, F. Deleo, J.C. Difrancesco, R. Di Giacomo, A. Di Liberto, E. Domina, F. Dono, V. Durante, M. Elia, A. Estraneo, G. Evangelista, M.T. Faedda, Y. Failli, E. Fallica, J. Fattouch, A. Ferrari, F. Ferreri, G. Fisco, D. Fonti, F. Fortunato, N. Foschi, T. Francavilla, R. Galli, S. Gazzina, A.T. Giallonardo, F.S. Giorgi, L. Giuliano, F. Habetswallner, F. Izzi, B. Kassabian, A. Labate, C. Luisi, M. Magliani, G. Maira, L. Mari, D. Marino, A. Mascia, A. Mazzeo, S. Meletti, C. Milano, A. Nilo, B. Orlando, F. Paladin, M.G. Pascarella, C. Pastori, G. Pauletto, A. Peretti, G. Perri, M. Pezzella, M. Piccioli, P. Pignatta, N. Pilolli, F. Pisani, L.R. Pisani, F. Placidi, P. Pollicino, V. Porcella, S. Pradella, M. Puligheddu, S. Quadri, P.P. Quarato, R. Quintas, R. Renna, G.R. Rizzo, A. Rum, E.M. Salamone, E. Savastano, M. Sessa, D. Stokelj, E. Tartara, M. Tombini, G. Tumminelli, A.E. Vaudano, M. Ventura, I. Viganò, E. Viglietta, A. Vignoli, F. Villani, E. Zambrelli, L. Zummo. - In: NEUROLOGY AND THERAPY. - ISSN 2193-8253. - (2022), pp. 1-16. [Epub ahead of print] [10.1007/s40120-022-00402-3]

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study

M.P. Canevini;F. Fortunato;A. Vignoli;
2022

Abstract

Introduction In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinuation. Safety and tolerability outcomes included the rate of treatment discontinuation due to adverse events (AEs) and the incidence of AEs. Data were compared for patients treated with add-on BRV after 1-2 (early add-on) and >= 3 (late add-on) prior antiseizure medications. Results A total of 1029 patients with focal epilepsy were included in the study, of whom 176 (17.1%) received BRV as early add-on treatment. The median daily dose of BRV at 12 months was 125 (100-200) mg in the early add-on group and 200 (100-200) in the late add-on group (p < 0.001). Sustained seizure response was reached by 97/161 (60.3%) of patients in the early add-on group and 286/833 (34.3%) of patients in the late add-on group (p < 0.001). Sustained seizure freedom was achieved by 51/161 (31.7%) of patients in the early add-on group and 91/833 (10.9%) of patients in the late add-on group (p < 0.001). During the 1-year study period, 29 (16.5%) patients in the early add-on group and 241 (28.3%) in the late add-on group discontinued BRV (p = 0.001). Adverse events were reported by 38.7% and 28.5% (p = 0.017) of patients who received BRV as early and late add-on treatment, respectively. Conclusion Brivaracetam was effective and well tolerated both as first add-on and late adjunctive treatment in patients with focal epilepsy.
Antiseizure medication; Brivaracetam; Epilepsy; Focal seizures;
Settore MED/39 - Neuropsichiatria Infantile
Settore MED/26 - Neurologia
16-set-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
s40120-022-00402-3.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 605.79 kB
Formato Adobe PDF
605.79 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/938188
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact